ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2024
Hydroxychloroquine monotherapy in sarcoidosis: Indications, efficacy, and side effects.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The efficacy and safety of hydroxychloroquine in patients with chronic inflammatory cardiomyopathy: a multicenter randomized study (HYPIC trial).BMC medicine · 2025Trial
- Advances in management of sarcoidosis-associated fatigue: A narrative review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis.International journal of molecular sciences · 2026Review
- A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders.The Lancet. Respiratory medicine · 2026Review
- Contemporary management of sarcoidosis.Frontiers in medicine · 2026Review
- Lymphocyte signal transduction defects in cutaneous sarcoidosis and implications for treatment.Frontiers in immunology · 2026Review
- Role of antimalarials in lupus nephritis: a narrative review.Clinical rheumatology · 2025Review
- Cardiac sarcoidosis recurrence post-heart transplant: A critical literature and case report.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Immunosuppressive Therapies in Pulmonary Sarcoidosis: A Practical, Evidence-Based Review.Journal of clinical medicine · 2025Review
- Hydroxychloroquine's diverse targets: a new frontier in precision medicine.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimIn sarcoidosis which is not threatening vital internal organs such as heart, central nervous system or lungs immunomodulatory treatment, such as hydroxychloroquine can be considered. Despite its common use, limited data are available regarding effectiveness and side effects as monotherapy in sarcoidosis. Recommendations on its usage are based on expert opinion as literature is scarce.
methodsThis retrospective study examines real-world data about the indications, effectivity and side effects of hydroxychloroquine monotherapy in sarcoidosis patients with no damage to the vital internal organs. Successful treatment was defined as continuation after 24 weeks without step up therapy or worsening of symptoms.
resultsSixty patients were eligible for the study. Starting dose was 400mg/day, lowered to 200mg/day after 3 months in most patients. The predominant treatment indications were musculoskeletal 45 (75%) and cutaneous involvement 13 (22%). Thirty-three patients (55%) continued treatment after 24 weeks. Twenty-four patients (40%) mentioned side effects, mainly gastrointestinal, leading to treatment discontinuation in eleven patients (18%). No severe side effects were seen. Continuation after 24 weeks was significantly higher in patients with cutaneous involvement compared to other indications 85% vs 47% respectively (p =0.02).
conclusionsTreatment with hydroxychloroquine monotherapy was satisfactory in 55% of patients, especially for cutaneous involvement. However, it poses considerable non-severe side-effects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.